Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Industry, Consumers Seek Greater Clarity In Hearing Aid Draft Guidance

This article was originally published in The Gray Sheet

Executive Summary

Companies and consumer groups asked FDA for a clearer distinction between hearing aid devices and personal sound amplification products in recent comments submitted in response to an FDA draft guidance.

You may also be interested in...

Trade Groups Protest OTC, QSR-Exempt Hearing Aids At FDA Meeting

Physicians and manufacturers alike expressed serious concerns with a proposal from White House advisors to make some hearing aids available over-the-counter and exempt from the Quality System Regulation at a recent FDA workshop. They argue the plan could endanger consumers without significantly lowering device costs.

FDA To Weigh Proposals For Lightened Hearing-Aid Regs

Following a White House report arguing that the current regulation of hearing aids is stifling innovation and raising costs, FDA has scheduled a gathering to discuss the future of hearing aid regulations. The agency has also reopened a comment period on a pending draft guidance. An industry trade group, however, is skeptical of proposals that have been put forward.

Regulatory Briefs: Draft Guidances On Hearing Aids, Syphilis Tests; Upcoming Panel Meetings

FDA issues draft guidance clarifying the difference between hearing aid devices and personal sound amplification products. Agency also issues draft guidance on the use of tests to screen human cells and tissues for syphilis. Boston Sci gets a new panel date for Watchman. More regulatory news.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts